Equities analysts predict that Pfizer Inc. (NYSE:PFE) will announce $0.75 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Pfizer’s earnings, with estimates ranging from $0.73 to $0.77. Pfizer posted earnings of $0.67 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 11.9%. The company is scheduled to announce its next earnings results on Tuesday, August 7th.
According to Zacks, analysts expect that Pfizer will report full-year earnings of $2.95 per share for the current fiscal year, with EPS estimates ranging from $2.91 to $3.01. For the next year, analysts expect that the business will post earnings of $3.05 per share, with EPS estimates ranging from $2.95 to $3.13. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Pfizer.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The business had revenue of $12.91 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter in the prior year, the company posted $0.69 earnings per share. Pfizer’s revenue was up 1.0% compared to the same quarter last year.
Several equities research analysts recently issued reports on the company. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday. Morgan Stanley reiterated a “buy” rating and set a $43.00 price target on shares of Pfizer in a report on Monday. Credit Suisse Group set a $39.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Monday. Societe Generale reiterated a “neutral” rating and set a $39.00 price target on shares of Pfizer in a report on Wednesday, May 30th. Finally, Jefferies Financial Group restated a “neutral” rating and issued a $39.00 price objective on shares of Pfizer in a research note on Monday, May 14th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $40.27.
Pfizer traded down $0.01, hitting $36.16, during trading on Friday, Marketbeat reports. 424,801 shares of the company were exchanged, compared to its average volume of 17,541,348. Pfizer has a 52 week low of $32.32 and a 52 week high of $39.43. The company has a market capitalization of $215.61 billion, a P/E ratio of 13.64, a price-to-earnings-growth ratio of 1.80 and a beta of 0.91. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.45.
The company also recently declared a quarterly dividend, which was paid on Friday, June 1st. Stockholders of record on Friday, May 11th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, May 10th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.76%. Pfizer’s dividend payout ratio is presently 51.32%.
In other news, EVP Laurie J. Olson sold 19,000 shares of the company’s stock in a transaction on Wednesday, June 6th. The stock was sold at an average price of $36.45, for a total transaction of $692,550.00. Following the transaction, the executive vice president now owns 98,644 shares of the company’s stock, valued at approximately $3,595,573.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ian C. Read sold 132,312 shares of the company’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total value of $4,764,555.12. The disclosure for this sale can be found here. Insiders have sold a total of 156,535 shares of company stock worth $5,647,222 in the last ninety days. Insiders own 0.06% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. South Dakota Investment Council lifted its holdings in Pfizer by 3.8% during the 3rd quarter. South Dakota Investment Council now owns 2,281,691 shares of the biopharmaceutical company’s stock worth $81,456,000 after purchasing an additional 83,150 shares in the last quarter. Ashburton Jersey Ltd lifted its holdings in Pfizer by 11.3% during the 3rd quarter. Ashburton Jersey Ltd now owns 35,350 shares of the biopharmaceutical company’s stock worth $1,262,000 after purchasing an additional 3,600 shares in the last quarter. Van Hulzen Asset Management LLC lifted its holdings in Pfizer by 5.9% during the 3rd quarter. Van Hulzen Asset Management LLC now owns 91,224 shares of the biopharmaceutical company’s stock worth $3,257,000 after purchasing an additional 5,055 shares in the last quarter. TD Asset Management Inc. lifted its holdings in Pfizer by 50.0% during the 3rd quarter. TD Asset Management Inc. now owns 7,585,517 shares of the biopharmaceutical company’s stock worth $270,803,000 after purchasing an additional 2,529,555 shares in the last quarter. Finally, Harwood Advisory Group LLC lifted its holdings in Pfizer by 24.1% during the 3rd quarter. Harwood Advisory Group LLC now owns 26,448 shares of the biopharmaceutical company’s stock worth $944,000 after purchasing an additional 5,130 shares in the last quarter. 69.49% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Get a free copy of the Zacks research report on Pfizer (PFE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.